Abstract: A modular fiber optic light line unit has a housing in which distal portions of one or more fiber optic bundles fan out such that termini of the fibers are arrayed in a continuous fiber row. The proximal ends of the bundles are held in respective sleeves, and light source modules are removably attached over the sleeves to generate light that is incident on the proximal end of the bundle. The light source modules are removably installed by pushing on, without requiring tools. The light source modules have a canister housing containing a solid-state light source, e.g., five watts. Heat management is achieved using fins on the modular housing. Different color wavelength light sources can be employed, and the fibers from the various bundles can be interleaved.

Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.

Abstract: A system for selecting and managing course materials utilizes websites having faculty, administrator, and publisher services pages. The faculty services page is accessible by faculty members to adopt specific course materials for specific courses. The website includes an administrative services page which is accessible by administrators to input course information and to review the course materials adopted by the faculty members and a publisher services portal which is accessible by publishers to review purchase information related to course materials adopted by the faculty members. A student services website is accessible by students to purchase adopted course materials for specific courses.

Abstract: An intracorporeal space filling device and a delivery system and method for using the device is disclosed. The space filling device is preferably configured for percutaneous delivery from a peripheral conduit of a patient. The space filling device has an elongated tubular or interconnected bead structure which may have a transmutable material disposed within it. The transmutable material can be altered from a non-rigid state to a rigid state by the application of various types of energy or by other suitable means. The space filling device can be positioned by a delivery system and detached from the delivery system after desired positioning is achieved.

Abstract: An intracorporeal space filling device and a delivery system and method for using the device is disclosed. The space filling device is preferably configured for percutaneous delivery from a peripheral conduit of a patient. The space filling device has an elongated tubular or interconnected bead structure which may have a transmutable material disposed within it. The transmutable material can be altered from a non-rigid state to a rigid state by the application of various types of energy or by other suitable means. The space filling device can be positioned by a delivery system and detached from the delivery system after desired positioning is achieved.

Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R4 are defined as in claim 1, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Abstract: The present invention relates to substituted imidazo-pyridinones and imidazo-pyridazinones of general formula wherein R1 to R4 are defined as in claim 1, the tautomers, the stereoisomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R4 are defined as in claim 1, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Abstract: An intracorporeal space filling device and a delivery system and method of using the device is disclosed. The space filling device is preferably configured for percutaneous delivery from a peripheral conduit of a patient. The space filling device has an elongated tubular or interconnected bead structure which may have a transmutable material disposed within it. The transmutable material can be altered from a non-rigid state to a rigid state by the application of various types of energy or by other suitable means. The space filling device can be positioned by a delivery system and detached from the delivery system after desired positioning is achieved.

Abstract: A wireless alarm system incorporates a battery powered transmitter and a battery powered receiver. The transmitter features an enlarged actuation button with a high point that, together with the hinge, describes a torque arm. The receiver unit incorporates an alarm and a receptacle for storing the transmitter unit. When a user pushes the button a signal is sent to the transmitter causing it to sound an audible alarm.

Abstract: An intracorporeal space filling device and a delivery system and method for using the device is disclosed. The space filling device is preferably configured for percutaneous delivery from a peripheral conduit of a patient. The space filling device has an elongated tubular or interconnected bead structure which may have a transmutable material disposed within it. The transmutable material can be altered from a non-rigid state to a rigid state by the application of various types of energy or by other suitable means. The space filling device can be positioned by a delivery system and detached from the delivery system after desired positioning is achieved.

Abstract: A fan assembly includes a vertical axis wind turbine (VAWT) which is coupled to an air extraction or air supply fan. The VAWT is located above and is coupled coaxially to the fan. The fan assembly also includes an auxiliary turbine to provide start-up torque to initiate rotation of the VAWT. The VAWT is typically a Darrieus-type turbine and the auxiliary turbine is typically a Savonius-type turbine. In the preferred embodiments, the fan assembly includes a rotational speed governor to avoid damage to the turbine and/or fan in high winds.

Abstract: A computer implemented method is provided for conducting business-to-business electronic commerce over the Internet. The method includes the step of providing a website that enables electronic communication with users, and including on the website an electronic shopping basket which is selectively actuatable into various states. An additional step includes enabling two or more remote users to simultaneously access the shopping basket. Each of the users is assigned one or more hierarchically distinct abilities to affect the state of the shopping basket, so that the users are permitted to simultaneously view the status of the shopping basket and sequentially affect the state of the shopping basket. This enables various actions in the purchasing process to be accomplished by various individuals. These abilities to affect the state of the basket may also include providing the users with various selected levels of access to the basket, i.e., to prevent unauthorized purchases.

Abstract: The invention relates to the use of angiotensin II receptor antagonists for treating people in whom type 2 diabetes mellitus has been diagnosed or who are suspected of prediabetes, for preventing diabetes or for treating metabolic syndrome and insulin resistance in patients with normal blood pressure.

Abstract: The present invention relates to substituted imidazo-pyridinones and imidazo-pyridazinones of general formula wherein Y and R1 to R4 are defined as in claim 1, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Abstract: The present invention relates to substituted imidazo-pyridinones and imidazo-pyridazinones of general formula wherein R1 to R4 are defined as in claim 1, the tautomers, the stereoisomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Abstract: A method for the prevention or treatment of a cardiovascular, cardiopulmonary, or renal disease or condition in a human or mammal patient, the method comprising administering to the patient in need thereof an effective amount of: (a) telmisartan or a polymorph or salt thereof; and (b) simvastatin.

Abstract: The present invention relates to a process for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases by improving endothelial function and achieving protection of organs, tissues and blood vessels in indications in which control of blood pressure and lipid levels are necessary, particularly in people in whom type 2 diabetes mellitus has been diagnosed or who are suspected of prediabetes, for preventing diabetes and prediabetes, or for the treatment of Metabolic Syndrome and insulin resistance in patients with normal blood pressure. The process comprises generally administering effective amounts of telmisartan or a polymorph or salt thereof and atorvastatin. The invention further relates to suitable pharmaceutical compositions which contain telmisartan or a polymorph or salt thereof and atorvastatin, as a combined preparation for simultaneous, separate or sequential use in the prevention or treatment of these diseases.

Abstract: The present invention relates to substituted piperazine derivatives of general formula wherein Ra, Rb, Rc, Rf, Rg, X, m and n are defined as in claim 1, the isomers and salts thereof, particularly the physiologically acceptable salts thereof, which are valuable inhibitors of the microsomal triglyceride-transfer protein (MTP), medicaments containing these compounds and their use, as well as the preparation thereof.

Abstract: The present invention relates to substituted piperazine derivatives of general formula wherein Ra, Rb, Rc Rf, Rg and m, n and X are defined as in claim 1, the isomers and salts thereof, particularly the physiologically acceptable salts thereof, which are valuable inhibitors of the microsomal triglyseride-transfer protein (MTP), medicaments containing these compounds and their use, as well as the preparation thereof.